Detalhe da pesquisa
1.
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
Cancer Sci
; 115(4): 1296-1305, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402853
2.
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
Br J Cancer
; 2024 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38519705
3.
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.
Invest New Drugs
; 42(1): 136-144, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38300341
4.
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
Cancer Sci
; 114(8): 3330-3341, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183528
5.
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.
BMC Cancer
; 23(1): 6, 2023 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36597021
6.
Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
Oncologist
; 27(9): 720-e702, 2022 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35759340
7.
Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.
Cancer Sci
; 112(8): 3255-3265, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34036692
8.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med
; 379(24): 2342-2350, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280658
9.
Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Invest New Drugs
; 39(1): 269-271, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32783090
10.
Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy.
Invest New Drugs
; 39(4): 1150-1158, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33483882
11.
Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320).
Invest New Drugs
; 39(2): 530-536, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33159674
12.
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Jpn J Clin Oncol
; 51(8): 1261-1268, 2021 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34037224
13.
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
N Engl J Med
; 377(20): 1919-1929, 2017 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28885881
14.
Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.
Invest New Drugs
; 38(6): 1854-1861, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32424780
15.
[An Analysis of Surgery for Colorectal Cancer Lung Metastasis].
Gan To Kagaku Ryoho
; 47(4): 700-702, 2020 Apr.
Artigo
em Japonês
| MEDLINE | ID: mdl-32389989
16.
[Laparoscopic Partial Hepatectomy for the Liver Metastasis of Gastric Cancer after Nab-Paclitaxel plus Ramucirumab Combination Therapy-A Case Report].
Gan To Kagaku Ryoho
; 47(13): 2065-2067, 2020 Dec.
Artigo
em Japonês
| MEDLINE | ID: mdl-33468802
17.
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.
Int J Cancer
; 144(5): 1170-1179, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30307035
18.
[A Case of Sigmoid Colon Cancer with Complete Visceral Inversion].
Gan To Kagaku Ryoho
; 46(6): 1073-1075, 2019 Jun.
Artigo
em Japonês
| MEDLINE | ID: mdl-31273179
19.
[A Case of Recurrent Gastric Cancer with Clinical Complete Response after Ramucirumab plus Paclitaxel Therapy].
Gan To Kagaku Ryoho
; 46(13): 1931-1933, 2019 Dec.
Artigo
em Japonês
| MEDLINE | ID: mdl-32157016
20.
Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation.
Invest New Drugs
; 36(4): 715-717, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29546681